Statistically significant (p<0.0001) and clinically meaningful improvement in Hamilton Anxiety Rating Scale (“HAM-A”) of ~10 ...

In early March 2026, Helus Pharma, a Cybin subsidiary, reported positive topline Phase 2 results for HLP004 as an adjunctive intramuscular treatment for adults with moderate-to-severe generalized ...

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, FDA alignment and a DSMB recommendation. Claim 70% Off TipRanks ...

The latest announcement is out from Cybin ( (HELP) ).

Discusses Phase II Results for HLP004 in Generalized Anxiety Disorder March 5, 2026 7:30 AM ESTCompany ParticipantsMichael Cola - ...

Canada based clinical-stage pharma Helus Pharma today announced top-line results from a Phase II signal detection study ...

Please provide your email address to receive an email when new articles are posted on . Treatment of generalized anxiety disorder with an antidepressant increased the treatment response rate by 41%.

Helus Pharma (HELP) stock falls as the company posts mid-stage trial data for HLP004, a psychedelic-based therapy for ...

Generalized anxiety disorder affects 1 in 20 U.S. adults. Those with serious symptoms may isolate themselves to the point they rarely leave their home and are unable to work and build meaningful ...

NEW YORK--(BUSINESS WIRE)--Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...

CLEVELAND — Researchers narrowed down what appears to be the correct dosage during a first ever rigorous clinical trial examining LSD as a treatment for generalized anxiety disorder, with results ...

Anxiety disorders are common. However, anxiety can also be a symptom of a general medical disorder or a side effect of a ...